Delving into the Latest Updates on B21 DNA vaccine(Fudan University) with Synapse

Overview

Basic Info

Drug Type

DNA vaccine, Prophylactic vaccine

Synonyms-

Target

Ag85B-ESAT-6 x Mt. Rv1738 antigen x Mt. Rv2029c antigen

Action

modulators, inhibitors

Mechanism

Ag85B-ESAT-6 modulators(Ag85B-ESAT-6 modulators), Mt. Rv1738 antigen inhibitors(Mt. Rv1738 antigen inhibitors), Mt. Rv2029c antigen inhibitors(Mt. Rv2029c antigen inhibitors)

Therapeutic Areas

Infectious Diseases

Active Indication

Latent Tuberculosis

Inactive Indication-

Originator Organization

Fudan University

Active Organization

Fudan University

Inactive Organization-

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Latent tuberculosis infection (LTBI) treatment is known to accelerate the decline in TB incidence, especially in high-risk populations. Mycobacterium tuberculosis (M. tb) expression profiles differ at different growth periods, and vaccines protective and therapeutic effects may increase when they include antigenic compositions from different periods. To develop a post-exposure vaccine that targets LTBI, we constructed four therapeutic DNA vaccines (A39, B37, B31, and B21) using different combinations of antigens from the proliferation phase (Ag85A, Ag85B), PE/PPE family (Rv3425), and latent phase (Rv2029c, Rv1813c, Rv1738). We compared the immunogenicity of the four DNA vaccines in C57BL/6j mice. The B21 vaccine stimulated the strongest cellular immune responses, namely Th1/Th17 and CD8+ cytotoxic T lymphocyte responses. It also induced the generation of strengthened effector memory and central memory T cells. In latently infected mice, the B21 vaccine significantly reduced bacterial loads in the spleens and lungs and decreased lung pathology. In conclusion, the B21 DNA vaccine can enhance T cell responses and control the reactivation of LTBI.

100 Deals associated with B21 DNA vaccine(Fudan University)

Login to view more data